Literature DB >> 11762576

Methylphenidate in the treatment of children with attention-deficit hyperactivity disorder.

B Vitiello1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11762576      PMCID： PMC81668     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  16 in total

Review 1.  Treatment of attention-deficit-hyperactivity disorder.

Authors:  J Elia; P J Ambrosini; J L Rapoport
Journal:  N Engl J Med       Date:  1999-03-11       Impact factor: 91.245

2.  Stimulant treatment for children: a community perspective.

Authors:  A Angold; A Erkanli; H L Egger; E J Costello
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-08       Impact factor: 8.829

3.  A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD.

Authors: 
Journal:  Arch Gen Psychiatry       Date:  1999-12

4.  Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial.

Authors:  C Gillberg; H Melander; A L von Knorring; L O Janols; G Thernlund; B Hägglöf; L Eidevall-Wallin; P Gustafsson; S Kopp
Journal:  Arch Gen Psychiatry       Date:  1997-09

Review 5.  An auditable protocol for treating attention deficit/hyperactivity disorder.

Authors:  P Hill; E Taylor
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

6.  Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA.

Authors:  B Vitiello; J B Severe; L L Greenhill; L E Arnold; H B Abikoff; O G Bukstein; G R Elliott; L Hechtman; P S Jensen; S P Hinshaw; J S March; J H Newcorn; J M Swanson; D P Cantwell
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

7.  Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.

Authors:  L L Greenhill; J M Swanson; B Vitiello; M Davies; W Clevenger; M Wu; L E Arnold; H B Abikoff; O G Bukstein; C K Conners; G R Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; H C Kraemer; J S March; J H Newcorn; J B Severe; K Wells; T Wigal
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2001-02       Impact factor: 8.829

Review 8.  National Institutes of Health Consensus Development Conference Statement: diagnosis and treatment of attention-deficit/hyperactivity disorder (ADHD)

Authors: 
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-02       Impact factor: 8.829

9.  Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.

Authors: 
Journal:  Pediatrics       Date:  2001-10       Impact factor: 7.124

Review 10.  Growth deficits in children with attention deficit hyperactivity disorder.

Authors:  T Spencer; J Biederman; T Wilens
Journal:  Pediatrics       Date:  1998-08       Impact factor: 7.124
View more
  6 in total

1.  Treatment of attention-deficit hyperactivity disorder.

Authors:  Laurence Jerome
Journal:  CMAJ       Date:  2002-05-14       Impact factor: 8.262

2.  Packages of care for attention-deficit hyperactivity disorder in low- and middle-income countries.

Authors:  Alan J Flisher; Katherine Sorsdahl; Sean Hatherill; Sonia Chehil
Journal:  PLoS Med       Date:  2010-02-23       Impact factor: 11.069

3.  The clinical impact of switching attention deficit hyperactivity disorder patients from OROS(®)-MPH to Novo-MPH ER-C(®): A paediatric practice review.

Authors:  Judy Pm van Stralen
Journal:  Paediatr Child Health       Date:  2013-02       Impact factor: 2.253

4.  Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day.

Authors:  Frank Lopez; Raul Silva; Linda Pestreich; Rafael Muniz
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

5.  Effectiveness and safety of a long-acting, once-daily, two-phase release formulation of methylphenidate (Ritalin ® LA) in school children under daily practice conditions.

Authors:  Fabian Haertling; Beate Mueller; Oliver Bilke-Hentsch
Journal:  Atten Defic Hyperact Disord       Date:  2014-10-28

6.  Bupropion, methylphenidate, and 3,4-methylenedioxypyrovalerone antagonize methamphetamine-induced efflux of dopamine according to their potencies as dopamine uptake inhibitors: implications for the treatment of methamphetamine dependence.

Authors:  Linda D Simmler; Rebecca Wandeler; Matthias E Liechti
Journal:  BMC Res Notes       Date:  2013-06-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.